Five-year Antibody Persistence and Safety Following a Booster Dose of Combined Haemophilus influenzae Type b–Neisseria meningitidis Serogroup C–Tetanus Toxoid Conjugate Vaccine

Randomized Trial to Compare the Immunogenicity and Safety of a CRM or TT Conjugated Quadrivalent Meningococcal Vaccine in Teenagers who Received a CRM or TT Conjugated Serogroup C Vaccine at Preschool Age

“…27 This might explain why Menitorix (O-acetylated) boosting induces protective MenC responses in more NeisVac-C-primed than Menitorixprimed children. 11 Our data support neither the proposal that CRMconjugated vaccines have inherently diminished immunogenicity 28 nor that priming and boosting with the same carrier protein is superior to priming and boosting with different carrier proteins. 9…”

“…9 In children primed with MCC-TT, Hib-MCC-TT or MCC-CRM, and then given MCC-TT at age 13-14 months, the MenC-protected proportion (SBA titers ≥8) at 5 years postbooster was highest in those primed with MCC-TT. 11 Better understanding of these interactions between priming and booster vaccines and carrier proteins would help further inform meningococcal vaccination policy, but this has not previously been studied in teenagers.…”

Antibody Persistence in Young Children 5 Years after Vaccination with a Combined Haemophilus influenzae Type b-Neisseria meningitidis Serogroup C Conjugate Vaccine Coadministered with Diphtheria-Tetanus-Acellular Pertussis-Based and Pneumococcal Conjugate Vaccines

“…There was no significant potential difference between groups in the percentages of children with anti-PRP antibody concentrations of ≥0.15 μg/ml, and there was no decline in comparison with earlier time points. Comparison of anti-PRP antibody GMCs between groups showed better long-term persistence 5 years after booster vaccination for the Hib-MenC-TT recipients than for the DTPa/Hib recipients, regardless of the coadministered pneumococcal conjugate vaccine, which is consistent with a previous report ( 23 ). There was only a slight decrease in the year 5 anti-PRP antibody GMC values, compared to the previous time points (up to 3 years after booster vaccination).…”

“…In that study, infants had been primed with two doses of MenC-CRM 197 or MenC-TT at 2 and 3 or 2 and 4 months of age ( 19 ). In contrast, in a study in Spain in which the GSK Vaccines rSBA-MenC assay was used, greater percentages were observed more than 5 years after Hib-MenC-TT booster vaccination in toddlers, following Hib-MenC-TT or MenC-TT priming in infancy on a 2/4/6-month schedule (78% to 97%) ( 23 ). However, these results cannot be directly compared with the current study results, as different rSBA assay procedures were used.…”

“…Primary vaccination induced persistent antibodies against both antigens up to the second year of life ( 12 – 15 ). Persistence rates after booster vaccination varied in different studies ( 22 , 23 , 27 ), and there are no data available regarding antibody persistence after coadministration with a pneumococcal conjugate vaccine.…”